Nothing Special   »   [go: up one dir, main page]

AP709A - Azetidines. - Google Patents

Azetidines. Download PDF

Info

Publication number
AP709A
AP709A APAP/P/1996/000901A AP9600901A AP709A AP 709 A AP709 A AP 709A AP 9600901 A AP9600901 A AP 9600901A AP 709 A AP709 A AP 709A
Authority
AP
ARIPO
Prior art keywords
formula
compound
alkyl
chnr
group
Prior art date
Application number
APAP/P/1996/000901A
Other languages
English (en)
Other versions
AP9600901A0 (en
Inventor
Alexander Roderick Mackenzie
Allan Patrick Marchington
Donald Stuart Marchington
Sandra Dora Meadows
Original Assignee
Pfizer Res & Dev
Pfizer Central Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev, Pfizer Central Res filed Critical Pfizer Res & Dev
Publication of AP9600901A0 publication Critical patent/AP9600901A0/xx
Application granted granted Critical
Publication of AP709A publication Critical patent/AP709A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/1996/000901A 1996-01-05 1996-12-19 Azetidines. AP709A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9600235.7A GB9600235D0 (en) 1996-01-05 1996-01-05 Therapeutic agents

Publications (2)

Publication Number Publication Date
AP9600901A0 AP9600901A0 (en) 1997-01-31
AP709A true AP709A (en) 1998-12-22

Family

ID=10786682

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000901A AP709A (en) 1996-01-05 1996-12-19 Azetidines.

Country Status (38)

Country Link
US (1) US6242438B1 (es)
EP (1) EP0871623B1 (es)
JP (2) JP3123611B2 (es)
KR (1) KR100275402B1 (es)
AP (1) AP709A (es)
AR (2) AR005339A1 (es)
AT (1) ATE232526T1 (es)
AU (1) AU708282B2 (es)
BG (1) BG102589A (es)
BR (1) BR9612412A (es)
CA (1) CA2237189C (es)
CO (1) CO4750815A1 (es)
CZ (1) CZ209398A3 (es)
DE (1) DE69626220T2 (es)
DK (1) DK0871623T3 (es)
DZ (1) DZ2155A1 (es)
ES (1) ES2190486T3 (es)
GB (1) GB9600235D0 (es)
HR (1) HRP970006A2 (es)
HU (1) HUP9903590A3 (es)
IL (2) IL124309A (es)
IS (1) IS1876B (es)
MA (1) MA26417A1 (es)
NO (1) NO311838B1 (es)
NZ (1) NZ324712A (es)
OA (1) OA10863A (es)
PE (1) PE29798A1 (es)
PL (1) PL185723B1 (es)
RU (1) RU2158264C2 (es)
SI (1) SI0871623T1 (es)
SK (1) SK89598A3 (es)
TN (1) TNSN96174A1 (es)
TR (1) TR199801268T2 (es)
TW (1) TW472054B (es)
UY (1) UY24429A1 (es)
WO (1) WO1997025322A1 (es)
YU (1) YU71496A (es)
ZA (1) ZA9747B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
ATE297906T1 (de) 1997-12-04 2005-07-15 Sankyo Co Alicyclische acylierte heterocyclenderivate
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
AU2001275524B2 (en) * 2000-06-12 2006-02-02 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0130261D0 (en) 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
AU2003299249B2 (en) * 2002-12-23 2010-05-27 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
CA2599186C (en) 2005-03-08 2014-12-09 Janssen Pharmaceutica N.V. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
TW201026666A (en) * 2008-12-16 2010-07-16 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
JP2012524802A (ja) * 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512901A1 (fr) * 1991-05-03 1992-11-11 Sanofi Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant
WO1996005193A1 (en) * 1994-08-09 1996-02-22 Pfizer Limited (azetidin-1-ylalkyl)lactams as tachykinin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69405862T2 (de) * 1993-05-06 1998-01-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512901A1 (fr) * 1991-05-03 1992-11-11 Sanofi Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant
WO1996005193A1 (en) * 1994-08-09 1996-02-22 Pfizer Limited (azetidin-1-ylalkyl)lactams as tachykinin antagonists

Also Published As

Publication number Publication date
NO982651L (no) 1998-06-09
DE69626220D1 (de) 2003-03-20
AR005338A1 (es) 1999-04-28
KR19990077027A (ko) 1999-10-25
AU708282B2 (en) 1999-07-29
HRP970006A2 (en) 1998-06-30
IL124309A (en) 2002-11-10
JP3123611B2 (ja) 2001-01-15
BG102589A (en) 1999-09-30
DZ2155A1 (fr) 2002-10-26
CA2237189C (en) 2002-09-03
SI0871623T1 (en) 2003-08-31
PL327665A1 (en) 1998-12-21
IL124309A0 (en) 1998-12-06
IS4760A (is) 1998-05-28
UY24429A1 (es) 2001-08-27
HUP9903590A2 (hu) 2000-05-28
PE29798A1 (es) 1998-06-11
NO982651D0 (no) 1998-06-09
EP0871623B1 (en) 2003-02-12
AR005339A1 (es) 1999-04-28
ES2190486T3 (es) 2003-08-01
TNSN96174A1 (fr) 2005-03-15
RU2158264C2 (ru) 2000-10-27
US6242438B1 (en) 2001-06-05
NO311838B1 (no) 2002-02-04
EP0871623A1 (en) 1998-10-21
IS1876B (is) 2003-05-28
BR9612412A (pt) 1999-07-13
KR100275402B1 (ko) 2000-12-15
YU71496A (en) 1999-11-22
ATE232526T1 (de) 2003-02-15
AP9600901A0 (en) 1997-01-31
PL185723B1 (pl) 2003-07-31
CA2237189A1 (en) 1997-07-17
GB9600235D0 (en) 1996-03-06
DE69626220T2 (de) 2003-08-28
JP3254205B2 (ja) 2002-02-04
MA26417A1 (fr) 2004-12-20
CZ209398A3 (cs) 1999-04-14
IL145324A0 (en) 2002-06-30
ZA9747B (en) 1998-09-30
WO1997025322A1 (en) 1997-07-17
JP2000344741A (ja) 2000-12-12
DK0871623T3 (da) 2003-03-31
HUP9903590A3 (en) 2002-01-28
NZ324712A (en) 1999-05-28
OA10863A (en) 2001-09-27
CO4750815A1 (es) 1999-03-31
TW472054B (en) 2002-01-11
AU1195097A (en) 1997-08-01
JPH11501667A (ja) 1999-02-09
SK89598A3 (en) 2000-02-14
TR199801268T2 (xx) 1998-10-21

Similar Documents

Publication Publication Date Title
AU689303B2 (en) (Azetidin-1-ylalkyl)lactams as tachykinin antagonists
AP709A (en) Azetidines.
DE69713075T2 (de) Piperidinone als tachykininantagoniste
EA002773B1 (ru) Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина
EP0791592B1 (en) Azetidines
KR100218626B1 (ko) 타키키닌 길항물질로서의 (아제티딘-1-일알킬)락탐
EP2211618A1 (en) Piperidinylhydroxyethylpiperidines as modulators of chemokine receptors
MXPA99012092A (es) Azetidinas
CZ9904659A3 (cs) Azetidinylpropylpiperidinové deriváty, meziprodukty a jejich použití jako tachykininových antagonistů